The TiMiSNAR-miRNA study aims to identify and validate microRNAs as potential blood-based biomarkers for assessing treatment response in locally advanced rectal cancer. This could address a significant unmet need in the oncology market, where current biomarkers (CEA and ctDNA) have limitations. If successful, the findings could lead to enhanced patient stratification and monitoring, potentially improving treatment outcomes and reducing healthcare costs. The study's focus on non-invasive liquid biopsies aligns with the growing trend towards personalized medicine and could position the sponsor favorably in the competitive landscape of cancer diagnostics.